To elucidate which specific immune cell population was responsible for our antitumor efficacy results, we used antibodies against CD4+ T cells, CD8+ T cells, or CD20+ B cells in ovarian cancer–bearing mice treated with RPE-mIL2. This evidence concerns the gene CD4 and ovarian carcinoma.